Koethe D, Llenos I C, Dulay J R, Hoyer C, Torrey E F, Leweke F M, Weis S
Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany.
J Neural Transm (Vienna). 2007;114(8):1055-63. doi: 10.1007/s00702-007-0660-5. Epub 2007 Mar 19.
The human endogenous cannabinoid system is an appealing target in the investigation of psychiatric disorders. In schizophrenia, endocannabinoids and their receptors are involved in the pathology of the disease. Previous studies reported an increased radioligand binding to cannabinoid receptors 1 (CB(1)) in schizophrenia, both in the dorsolateral prefrontal cortex and in the anterior cingulate cortex (ACC). We analyzed the expression of the CB(1) receptors in the ACC at the protein level using immunohistochemistry. In a quantitative postmortem study, 60 patients suffering from schizophrenia, bipolar disorder, major depression and controls were included. Numerical densities of neurons and glial cells immunopositive for CB(1) receptors were evaluated. No evidence of an increased or decreased density of CB(1) receptor immunopositive cells in schizophrenia or bipolar disorder was found. In major depression, CB(1) receptor immunopositive glial cells in the grey matter were decreased. Furthermore, our data show that different medications have an impact on the expression of CB(1) receptors in the ACC.
人类内源性大麻素系统是精神疾病研究中一个有吸引力的靶点。在精神分裂症中，内源性大麻素及其受体参与了该疾病的病理过程。先前的研究报道，在精神分裂症患者的背外侧前额叶皮质和前扣带回皮质（ACC）中，放射性配体与大麻素受体1（CB(1)）的结合增加。我们使用免疫组织化学方法在蛋白质水平分析了ACC中CB(1)受体的表达。在一项定量尸检研究中，纳入了60名患有精神分裂症、双相情感障碍、重度抑郁症的患者以及对照组。对CB(1)受体免疫阳性的神经元和胶质细胞的数量密度进行了评估。未发现精神分裂症或双相情感障碍中CB(1)受体免疫阳性细胞密度增加或减少的证据。在重度抑郁症中，灰质中CB(1)受体免疫阳性的胶质细胞减少。此外，我们的数据表明，不同药物对ACC中CB(1)受体的表达有影响。
